Trial Profile
Open Randomized Trial Examining the Growth and Safety Effects of Treatment With Recombinant Growth Hormone on Infants Aged 1 to 2 Years With Growth Retardation Secondary to Chronic Renal Insufficiency
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Growth disorders
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Novo Nordisk
- 12 Apr 2014 New trial record